Goodwill and Other Intangible Assets

3 Months Ended

Mar. 31, 2012

Note 8 – Goodwill and Other Intangible Assets

The changes in the carrying amount of goodwill, by reportable segment during 2012 were as follows (in thousands):

	Cell Therapy - United States		Pharmaceutical Manufacturing - China		Total

Balance as of December 31, 2011	$	11,117.8	$	8,495.7	$	19,613.5

Foreign currency exchange rate changes		-		53.0		53.0

Balance as of March 31, 2012	$	11,117.8	$	8,548.7	$	19,666.5

As of March 31, 2012 and December 31, 2011, the Company’s intangible assets and related accumulated amortization consisted of the following (in thousands):

		March 31, 2012							December 31, 2011
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 Years	$	19,488.4	$	(4,588.1	)	$	14,900.3	$	19,373.8	$	(4,076.1	)	$	15,297.7
Manufacturing technology	10 Years		8,810.3		(1,595.4	)		7,214.9		8,779.9		(1,368.9	)		7,411.0
Tradename	10 Years		1,825.5		(343.9	)		1,481.6		1,819.0		(296.9	)		1,522.1
In process R&D	Indefinite		11,201.6		-			11,201.6		11,190.4		-			11,190.4
Standard operating procedures	10 Years		1,111.8		(268.7	)		843.1		1,104.9		(239.4	)		865.5
VSEL patent rights	19 Years		669.0		(149.6	)		519.4		669.0		(140.8	)		528.2
Patents	8 Years		205.5		(92.5	)		113.0		204.3		(86.8	)		117.5
Total Intangible Assets		$	43,312.1	$	(7,038.2	)	$	36,273.9	$	43,141.3	$	(6,208.9	)	$	36,932.4

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):

	Three Months Ended March 31,
	2012		2011
Cost of revenue	$	248.1	$	341.0
Research and development		13.9		13.7
Selling, general and administrative		533.2		521.7
Total	$	795.2	$	876.4

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details